Skip to main content
ALGS logo

ALGS

Aligos Therapeutics, Inc.
$6.73 +0.64 (+10.51%) At close · Jul 8
Market Cap
$24.29M
Shares
3,587,892

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$2.19M -39.5%
FY2025 Revenue FY2020–FY2025
Net Income
-$24.19M +81.6%
FY2025 Net Income FY2019–FY2025
Operating Margin
-4024.93% -1556pp
FY2025 Operating Margin FY2023–FY2025
Diluted EPS
-$2.45 +88.3%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$82.5M -2.2%
FY2025 Operating Cash Flow FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
$4.71M $2.19M $3.61M $6.19M $0 $0 $0
$1.5M $2.2M $1.7M $4.3M $1.5M
$78.3M $69.45M $70.27M $73.04M $85.08M $104.15M $79.89M $44.04M
$22.07M $20.72M $22.83M $30.62M $26.41M $28.53M $17.94M $10.01M
$100.38M $90.17M $93.1M $103.66M $111.49M $132.68M $97.83M $54.04M
-$95.67M -$87.99M -$89.15M -$88.13M -$97.58M -$128.32M -$97.83M -$54.04M
-4024.93% -2468.96% -1423.47%
-$89.73M -$23.88M -$130.88M -$86.88M -$95.94M -$128.19M -$108.38M -$52.18M
$588K $314K $331K $795K $106K $143K $161K $85K
-$90.32M -$24.19M -$131.21M -$87.68M -$96.05M -$128.33M -$108.54M -$52.26M
-1106.72% -3633.65% -1416.23%
-$90.33M -$24.18M -$131.31M -$87.54M -$96.1M -$127.69M -$108.62M -$52.38M
USD/shares -$2.45 -$20.94 -$34.20 -$56.25
USD/shares -$2.45 -$20.94 -$34.20 -$56.25
shares 9.88M 6.26M 2.56M 1.71M 1.59M 399.53K 80.29K
shares 9.88M 6.26M 2.56M 1.71M 1.59M 399.53K 80.29K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Key facts CIK 1799448 CUSIP 01626L204 13F (30d) 2 filings 2 filers Visit website Investor relations